Skip to main content
SpringerLink
Log in

Clinical Trials in the Era of Treatment Tailoring

  • Chapter
Breast Cancer and Molecular Medicine

  • 994 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Piccart M, Colozza MA, Sotiriou C, Cardoso F. Tailored systemic treatment for breast cancer: dream or reality? Eur J Cancer, 3:2–5, 2004.

    Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer. Overview of the randomized trials. Lancet, 348:1189–1196, 1996.

    Article  Google Scholar 

  3. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 351:1451–1467, 1998.

    Article  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet, 352:930–942, 1998.

    Article  Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group. 2000 analysis overview results. Fifth meeting of the Early Breast Cancer Trialists’ Collaborative Group, Oxford, UK, September 21–23, 2000.

    Google Scholar 

  6. National Institutes of Health Consensus Development Conference. J Natl Cancer Inst Monogr, 30:1–152, 2001.

    Google Scholar 

  7. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst, 90:1601–1608, 1998.

    Article  PubMed  CAS  Google Scholar 

  8. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol, 8:103–112, 1990.

    PubMed  CAS  Google Scholar 

  9. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10:1049–1056, 1992.

    PubMed  CAS  Google Scholar 

  10. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups. N Engl J Med, 345:1378–87, 2001.

    Article  PubMed  CAS  Google Scholar 

  11. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG et al. ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359:2131–2139, 2002.

    Article  PubMed  CAS  Google Scholar 

  12. Piccart M, Goldhirsch A, Straehle C. The Breast International Group. A new spirit of collaboration in breast cancer treatment for the new millennium. Eur J Cancer, 36:1733–1736, 2000.

    Article  PubMed  CAS  Google Scholar 

  13. Wils J. The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br J Cancer, 77Suppl 2:23–28, 1998.

    PubMed  Google Scholar 

  14. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res, 9:5078–5084, 2003.

    PubMed  CAS  Google Scholar 

  15. van’t Veer LJ, Weigelt B. Road map to metastasis. Nat Med, 9:999–1000, 2003.

    Article  CAS  Google Scholar 

  16. Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med, 350:1814–1816, 2004.

    Article  PubMed  CAS  Google Scholar 

  17. Gelber RD, Bonetti M, Castiglione-Gertsch M, Coates AS, Goldhirsch A for the International Breast Cancer Study Group (IBCSG). Tailoring adjuvant treatments for the individual breast cancer patient. Breast, 12:558–568, 2003.

    Article  PubMed  CAS  Google Scholar 

  18. Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res, 9:486S–494S, 2003.

    PubMed  CAS  Google Scholar 

  19. Tockman MS, Gupta PK, Pressman NJ, Mulshine JL. Considerations in bringing a cancer biomarker to clinical application. Cancer Res, 52(Suppl 9):2711S–2718S, 1992.

    PubMed  CAS  Google Scholar 

  20. Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N et al. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn, 4:169–188, 2004.

    Article  PubMed  CAS  Google Scholar 

  21. Pusztai L, Hess KR. Design and integration of transcriptional profiling studies into clinical trials. Educational Book Am Soc Clin Oncol, 153–158, 2004.

    Google Scholar 

  22. Simon R. Development and validation of gene expression-based diagnostic classification in clinical oncology. Educational Book Am Soc Clin Oncol, 149–152, 2004.

    Google Scholar 

  23. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol, 23:2020–2027, 2005.

    Article  PubMed  Google Scholar 

  24. Paik S. Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnol Annu Rev, 9:259–267, 2003.

    Article  PubMed  Google Scholar 

  25. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat, 24:195–208, 1993.

    Article  PubMed  CAS  Google Scholar 

  26. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst, 94:116–128, 2002.

    PubMed  CAS  Google Scholar 

  27. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415:530–536, 2002.

    Article  Google Scholar 

  28. Paik S, Shak S, Tang G, Kim C, Baker J, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 351:2817–2826, 2004.

    Article  PubMed  CAS  Google Scholar 

  29. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 347:1999–2009, 2002.

    Article  PubMed  Google Scholar 

  30. Zalcberg JR, Verweij J, Casali PG, LeCesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) — an international, intergroup study of the EORTC, ISG and AGITG. Proc Am Soc Clin Oncol, 23:815, 2004 (abstr 9004).

    Google Scholar 

  31. Rankin C, Von Mehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST — Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol, 23:815, 2004 (abstr 9005).

    Google Scholar 

  32. Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist, 9:259–270, 2004.

    Article  PubMed  CAS  Google Scholar 

  33. Kim JA. Targeted therapies for the treatment of cancer. Am J Surg, 186:264–268, 2003.

    Article  PubMed  CAS  Google Scholar 

  34. Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin Oncol, 31(1 Suppl 3):21–7, 2004.

    Article  PubMed  CAS  Google Scholar 

  35. Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev, 17:333–340, 2003.

    PubMed  Google Scholar 

  36. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol, 5:292–302, 2004.

    Article  PubMed  CAS  Google Scholar 

  37. Roberts TG Jr, Lynch JT Jr, Chabner BA. The phase III trial in the era of targeted therapy: unraveling the “Go or no Go” decision. J Clin Oncol, 21:3683–3695, 2003.

    Article  PubMed  CAS  Google Scholar 

  38. Eckhardt GS, Eisenhauer EA, Parulekar WR, Pazdur R, Hirschfeld S. Development therapeutics: successes and failures of clinical trial designs of targeted compounds. Educational Book Am Soc Clin Oncol, 209–219, 2003.

    Google Scholar 

  39. Parulekar WR, Eisenhauer EA. Novel endpoints and design of early clinical trials. Ann Oncol, 13(suppl 4):139–143, 2002.

    PubMed  Google Scholar 

  40. Green MR. Targeting targeted therapy. N Engl J Med, 350:2191–2193, 2004.

    Article  PubMed  CAS  Google Scholar 

  41. Gianni L. The future of targeted therapy: combining novel agents. Oncology, 63(suppl 1):47–56, 2002.

    Article  PubMed  CAS  Google Scholar 

  42. Goldman B. For investigational targeted drugs, combination trials pose challenges. J Natl Cancer Inst, 95:1744–1746, 2003.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. EORTC Data Centre, Avenue E Mounier 83/Boîte 11, Brussels, 1200, Belgium

    P. Therasse & J. Bogaerts

Authors
  1. P. Therasse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Bogaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium

    Martine J. Piccart MD, PhD  & Fatima Cardoso MD  & 

  2. Anderson Cancer Center, The University of Texas MD, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA

    Mien-Chie Hung PhD

  3. Dept. of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-4283, USA

    Lawrence J. Solin MD

  4. Dept. of Surgery, Emory University Hospital, 1364 Clifton Road NE B206, Atlanta, Georgia, 30322-1059, USA

    William C. Wood MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Therasse, P., Bogaerts, J. (2006). Clinical Trials in the Era of Treatment Tailoring. In: Piccart, M.J., Hung, MC., Solin, L.J., Cardoso, F., Wood, W.C. (eds) Breast Cancer and Molecular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28266-2_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28266-2_46

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28265-5

  • Online ISBN: 978-3-540-28266-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation